click enter text
merck report financi result wednesday morn
open compani came margin weaker revenu in-lin
ep
gave revenu ep guidanc in-lin
compani surpris investor announc spin part
busi total revenu new publicly-trad
compani view separ increas manag
abil narrow focu fit trend seen across industri often
doubt herald chang manag think toward
futur unlik similar transact announc howev
one seem destroy valu sotp basi fortun rather
seem modestli value-cr
make margin chang forecast keep pt intact
rate outperform inform stock
cover see global pharmaceut januari issu monthli
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
wednesday open merck
report result slight miss consensu revenu in-lin ep
revis revenu ep guidanc in-lin consensu
announc would spin collect product core busi narrow focu
saw stock drop under-perform peer group broader market
overal impress report result wednesday morn open financi result
okay great touch light rev keytruda/gardasil bit lighter ep beat penni
guidanc in-lin clearli greater focu remain newly-announc decis
spin portion pharmaceut busi new publicly-trad compani
immedi conjur imag recent move spin portion busi sell
differ type maneuv took pfe share price lower pfe case share price
declin differ reason along split news simultan announc upjohn
busi spun go signific revenu shortfal rel analyst
model spin contract negative-growth busi perpetu seem
put hand mean suddenli got accord myl-lik price-to-earnings multipl destroy
valu sotp basi also made clear residu would fewer dividend increas
share buyback go forward none spin newco guidanc
revenu growth ahead low singl digit shortfal revenu base newco
guid remainco dividend remain intact grow newco also pay
sustain dividend say continu share buyback usual newco may
guid combin remainco newco situat mean combin
revenu earn dividend higher sharehold new structur cours
year compar today say initi nomin dilut
separ transact cost otherwis combin outlook believ
enhanc mean sotp basi compani reliabl growth front
problem preliminari sotp analysi support view
show transact modestli value-cr avail upon request
biggest critic decis predict remain even depend
overli depend bear case goe keytruda newer worri among investor
last sever month one view overdon ye eventu major problem
keytruda goe away first loe essenti start full away yet earli realist
worri proxim keytruda face varieti competit threat face
along form competitor tri take share away addit read-out across io categori
unpredict par cours nearli everi major product major diseas area
keytruda sale advanc nearli y/i product still straight
mint money drug compani product like transform growth
cash flow bring eventu parti end keytruda account total combin
sale split occur percentag rise major chang
one thing may caus share price weak probabl guidanc
miss consensu continu discuss whether margin expans keytruda
page
could come flood mrk faster manag guid given big
perform steadfast messag would still invest year
like hope nonetheless guidanc would higher didnt know expect realli
guidanc encompass current forecast
taken togeth given valuat price-to-earnings group averag above-averag growth
outlook durabl mani year continu find valu name maintain
outperform rate believ mrk reason split newco manag describ
abl focu busi matter simplifi organ structur doubt
herald chang mrk think futur fit mani drug compani
last year similarli narrow focu shrink base someth
manag inform drug stock cover see recent report global
 januari issu monthli controversi report
term sale ep exhibit
revenu report sale vs our/consensu
non-gaap ep report vs consensu
keytruda sale vs consensu
gardasil sale vs consensu larg rare miss
revenu vs consensu
ep non-gaap ep vs consensu
spin-off newco spin-off spin-off women health biosimilar legaci asset annual sale
newco receiv tax-fre dividend upon close newco
revenu increas minim ep increas
revenu estim chang ep estim chang
depend year
page
ep compound-annual-growth-rate ep compound-annual-growth-rate stay vs prior repres
price target unchang repres unchang multipl new
describ spin creat two lead growth compani newco global leader women
health buttress ta like pain dermatolog biosimilar believ outlook
combin compani under-appreci street see consensu low
revenu oper margin ep yet refrain give specif guidanc metric
guidanc revenue growth rev build fx gm opex increas lsd growth
sg remain tightli manag tax rate share ep
y/i growth emb fx impact
initi op margin remainco declin slightli due separ grow time
dividend unaffect remainco new newco dividend also continu
newco rev op margin current part independ compani low sd
revenue growth revenu base op margin rang initi increas time
ebidta low mid rang also increas time meaning dividend
combin ep nomin lower spin higher post spin due unlock growth
organ
newco expect flat declin within separ compani grow
expect declin initi vs larg due schcedul loe nuvar us zetia
ja meaning beyond add bd describ women health key ta
along biosimilar nexplanon reach sale biosimilar rev approx
grow beyond two area sale pain also focu meaning
dividend share buyback
 time gave view larg non-specif answer question
partli relat keytruda gener higher cash flow support remainco
 oper effici net reduct vs prior combin compani spend
exactli increment within remainco
page
 newco real high-qual time newco build effort select area
women health
 updat view remainco plan anim health like ever keep perpetu
say would never commit know lt plan bc alway reassess look
ah today continu believ best owner busi go forward key growth
pillar help support oper
 leav januvia within remainco newco still want research cardiometabol
area also gener lot cash flow re-deploy area even goe
loe growth year
 comment bullish consensu elabor
reiter prior talk point underappreci revs/op margins/ep
 stand alon remainco ep declin say assumpt give credit
oper effici first year give credit cash infus remainco
go share repurchas dilut like rang dilut remainco current
 revenu line put newco fact go
specif
 focu potenti target pipelin side look accret deal
replac ep capit alloc prioriti remain unchang chose spin quickest way
tax-effici way chang sort thing look
 opmargin lower initi remainco newco today higher op margin ye initi dilut
remainco ep first year even first year op synergi second year
third year percentag point dilut opmargin first year continu
grow surpass would ordinarili
 long-term relationship newco tbd term could
help compani
 spin impact ahead split date chang near-term long-term prioriti
plan ampl capit whatev want
 tax rate impact spin meaning chang
 split impact organ realli impact plan time newco build
 organ time
much contribut china perform newco revenu base china grew broad-
base across keytruda oncolog product januvia nrdl zepati nrdl clear answer
page
reimburs data major market
 pleas speak confid level broader adjuv opportun
bullish past recent failur timelin sometim slip etc
anyth concern said cant speak broader opportun across compani
keytruda remain confid alreadi evid adjuv benefit neoadjuv breast
mel given natur biolog earli cancer shouldnt realli expect timelin pull forward
defin cadenc base success prior two set expect continu success futur
 keytruda concentr competit pressur point could emerg time
chines produc healthcar reform other pleas increment sale growth
nearli lung roll global drive strength respons concentr question talk
oncolog non-oncolog brand gener comment make repeat
industri view support move
 format newco take leverag keytruda even high isnt concern say
concentr increas small amount product help driver higher growth remainco
talk oncolog product non-oncolog product line
 keytruda price cut ja discuss feb statutori reduct face anoth
statutori reduct april rang feb price cut impact ja despit near-term
impact still abl grow ja time
 outlook china nrdl lung make unsolicit remark like china impact
busi due coronaviru lung cancer note keytruda still approv
china signific opportun self-pay market wolf comment recal get nrdl went
local compani
 neoaduv tnbc data gave specif time
 view tigit program work time work well combo
keytruda tbd remain enthusiast move forward continu develop wolf
comment potenti import tigit tecentriq vs tecentriq phase data lung read
need monitor discuss particular trial manag late
found highlight pipelin unplug call
senior leadership
gardasil weaker stock-pil payback cdc impact quarter
page
 updat manufactur expans outlook continu see strong demand
around world still abl satisfi demand growth slightli temper
rel constraint still track bring two new manufactur facil
bring lot new suppli exhibit show compani report actual result vs
estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
newoldnewtot marginroughli tightli expensesincreas singl digit rate guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
exhibit wr merck balanc sheet cash flow statement
page
flow statement incom incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
